Revenue: As of FY2026 Q2, the actual value is USD 1.308 B, beating the estimate of USD 1.29 B.

EPS: As of FY2026 Q2, the actual value is USD 0.64, beating the estimate of USD 0.6031.

EBIT: As of FY2026 Q2, the actual value is USD 304.4 M.

Revenue

DexCom, Inc. reported worldwide revenue of $1.308 billion for the second quarter of 2026, marking an increase of 13% year-over-year on a reported basis and 12% year-over-year on an organic basis. U.S. revenue grew 11% year-over-year, while international revenue increased 19% on a reported basis and 16% on an organic basis year-over-year. Total revenue for the second quarter was $1,308.4 million, with $933.4 million from the United States and $375.0 million internationally. Distributor revenue totaled $1,102.4 million, comprising $893.5 million from the U.S. and $208.9 million internationally. Direct revenue was $206.0 million, with $39.9 million from the U.S. and $166.1 million internationally.

Gross Profit

GAAP gross profit totaled $830.0 million, or 63.4% of revenue, for the second quarter of 2026, an increase from $688.8 million or 59.5% of revenue in the prior year. Non-GAAP gross profit was $838.5 million, or 64.1% of reported revenue, compared to $695.9 million or 60.1% of reported revenue in the second quarter of 2025.

Operating Income

GAAP operating income for the second quarter of 2026 was $318.3 million, representing 24.3% of revenue and a 590 basis point increase compared to the second quarter of 2025. Non-GAAP operating income was $328.3 million, or 25.1% of reported revenue, also marking a 590 basis point increase year-over-year.

Net Income

GAAP net income for the second quarter of 2026 was $249.1 million. Non-GAAP net income was $269.1 million.

Operating Expenses

Research and development expenses were $153.0 million for the second quarter of 2026. Selling, general and administrative expenses amounted to $358.7 million for the same period. Total operating expenses were $511.7 million.

Cash and Liquidity

As of June 30, 2026, DexCom, Inc. held $1.95 billion in cash, cash equivalents, and marketable securities. The company’s revolving credit facility remained undrawn.

Other Financial Metrics

Other income (expense), net was - $0.8 million. Income tax expense was $68.4 million. Adjusted EBITDA reached $421.3 million.

Balance Sheet Highlights (June 30, 2026)

Cash and cash equivalents were $1,105.0 million, and short-term marketable securities were $842.0 million. Accounts receivable, net, stood at $1,257.7 million, and inventory was $726.4 million. Total current assets were $4,086.6 million, while total assets amounted to $6,455.3 million. Accounts payable and accrued liabilities were $2,191.5 million, and total current liabilities were $2,357.7 million. Total liabilities amounted to $3,833.9 million. Retained earnings were $2,882.5 million, and treasury stock was - $2,728.0 million. Total stockholders’ equity was $2,621.4 million.

Outlook / Guidance

DexCom, Inc. is raising the midpoint of its fiscal year 2026 revenue guidance to a range of $5.18 - $5.25 billion, representing approximately 11-13% growth. The company also increased its fiscal year 2026 guidance for Non-GAAP Gross Profit Margin to approximately 64% and Non-GAAP Operating Margin to approximately 23.5-24%. Additionally, the Adjusted EBITDA Margin guidance was raised to approximately 31.5-32%.